Press Releases Featured Jan 9, 2024 Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy Jan 9, 2024 Jan 9, 2024 Sep 2, 2022 Oak Hill Bio to Participate in Citi 17th Annual BioPharma Conference Sep 2, 2022 Sep 2, 2022 Aug 25, 2022 Oak Hill Bio Joins C-Path’s International Neonatal Consortium Aug 25, 2022 Aug 25, 2022 May 27, 2022 Oak Hill Bio to Participate in 2022 Wells Fargo Private Biotech Symposium May 27, 2022 May 27, 2022 May 25, 2022 Oak Hill Bio Sponsors Industry Symposium at International Conference on Clinical Neonatology May 25, 2022 May 25, 2022 May 17, 2022 2022 RBC Capital Markets Global Healthcare Conference May 17, 2022 May 17, 2022 May 12, 2022 Oak Hill Bio to Present at 2022 RBC Capital Markets Global Healthcare Conference May 12, 2022 May 12, 2022 Feb 1, 2022 Oak Hill Bio Launches with Pipeline and Senior Leadership from Takeda Feb 1, 2022 Feb 1, 2022 In the News Featured May 20, 2022 Endpoints Ex-Takeda exec hits the ground running at the helm of rare disease biotech — with 3 priorities off the bat May 20, 2022 Endpoints May 20, 2022 Endpoints Feb 1, 2022 Endpoints Takeda spins PhII rare disease programs into new startup — sending 2 execs and some cash to get things going Feb 1, 2022 Endpoints Feb 1, 2022 Endpoints Feb 1, 2022 Biocentury New start-up Oak Hill to advance ‘de-prioritized’ Takeda rare disease candidates Feb 1, 2022 Biocentury Feb 1, 2022 Biocentury Feb 1, 2022 Fierce Biotech Takeda shunts jewel of Shire takeover to new spinoff Oak Hill Feb 1, 2022 Fierce Biotech Feb 1, 2022 Fierce Biotech